Within the LFB Group, which is a leader in the field of therapeutic proteins in France, LFB USA enables the production of life-saving medicines within the Group’s key areas of expertise and focus – immunology, intensive care and hemostasis. By providing development, manufacturing, quality control, quality assurance, clinical and regulatory capabilities and services, LFB USA is cultivating life-changing therapeutic proteins for patients with serious and often rare diseases.

The company is leveraging our rPRO Technology™ to develop much-needed innovative therapeutic proteins for patients with serious and rare diseases - high potential medicinal products from LFB S.A.’s pipeline. The most advanced of these programs is a proprietary recombinant form of human Factor VIIa which is being evaluated in a Phase III clinical trial in patients with congenital hemophilia A or B with inhibitors.

In an effort to continually explore additional medicines made possible by this unique approach to therapeutic protein development, LFB USA is also a services provider to other organizations who share our vision.

Interested in learning more? Contact LFB USA Business Development by email.